

CMS Manual System	Department of Health & Human Services (DHHS)
Pub 100-04 Medicare Claims Processing	Centers for Medicare & Medicaid Services (CMS)
Transmittal 12949	Date: November 8, 2024
	Change Request 13861

SUBJECT: National Fee Schedule for Medicare Part B Vaccine Administration CMS - January 2025

I. SUMMARY OF CHANGES: The purpose of this change request (CR) is to provide instructions for the Medicare contractors to download, test, and implement the annual Part B Preventive Vaccine Administration file. The rates from the new annual Part B Preventive Vaccine Administration file will be applied to preventive service claims beginning January 1, 2025.

EFFECTIVE DATE: January 1, 2025

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: January 6, 2025

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated)

R=REVISED, N=NEW, D=DELETED-Only One Per Row.

R/N/D	CHAPTER / SECTION / SUBSECTION / TITLE
N/A	N/A

III. FUNDING:

For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

IV. ATTACHMENTS:

Recurring Update Notification

Attachment - Recurring Update Notification

Pub. 100-04	Transmittal: 12949	Date: November 8, 2024	Change Request: 13861
-------------	--------------------	------------------------	-----------------------

SUBJECT: National Fee Schedule for Medicare Part B Vaccine Administration CMS - January 2025

EFFECTIVE DATE: January 1, 2025

**Unless otherwise specified, the effective date is the date of service.*

IMPLEMENTATION DATE: January 6, 2025

I. SUMMARY OF CHANGES: The purpose of this change request (CR) is to provide instructions for the Medicare contractors to download, test, and implement the annual Part B Preventive Vaccine Administration file. The rates from the new annual Part B Preventive Vaccine Administration file will be applied to preventive service claims beginning January 1, 2025.

II. GENERAL INFORMATION

A. Background: CR 12943 implemented a national fee schedule for Medicare Part B vaccine administration.

B. Policy: The national fee schedule for Medicare Part B vaccine administration reflects Healthcare Common Procedure Coding System (HCPCS) codes that are payable for dates of services beginning January 1, 2025. The payment amounts are updated to reflect the annual increase in the Medicare Economic Index and are subsequently adjusted for geographic locality using the Geographic Adjustment Factor (GAF), based upon the Physician Fee Schedule locality where the preventive vaccine is administered. These adjustments apply to HCPCS codes G0008, G0009, G0010, 90480, and the in-home add-on payment (HCPCS code M0201).

Medicare will continue to cover and pay COVID-19 monoclonal antibody products for post-exposure prophylaxis or treatment of COVID-19 under the Part B preventive vaccine benefit through the end of the calendar year in which the Secretary ends the current Emergency Use Authorization declaration for COVID-19 drugs and biologicals. Relevant HCPCS codes for COVID-19 monoclonal antibody products and their administration can be found on the CMS COVID-19 Vaccine Pricing website at <https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price/vaccine-pricing>, under “COVID-19 Vaccines & Monoclonal Antibodies.” Please note that as of the issuance of this CR, there are no COVID-19 monoclonal antibodies approved or authorized for post-exposure prophylaxis or treatment against the dominant strains of COVID-19 in the United States.

Medicare will continue to cover and pay for monoclonal antibodies that are used for pre-exposure prophylaxis (PrEP) of COVID-19 under the Part B preventive vaccine benefit even after the EUA declaration for drugs and biological products is terminated, so long as after the EUA declaration is terminated, such products have market authorization and meet applicable coverage requirements. The payment amount for the administration of monoclonal antibodies used for PrEP of COVID-19 is adjusted for geographic locality using the Geographic Adjustment Factor, based upon the Physician Fee Schedule locality where the preventive vaccine is administered. On March 22, 2024, the FDA issued an EUA for Pempgarda (pemivibart) injection, for intravenous use. Pempgarda is a monoclonal antibody product authorized for emergency use for pre-exposure prophylaxis to help prevent COVID. Therefore, the GAF adjustment applies to HCPCS code M0224 for the administration of Pempgarda. More information on COVID-19 monoclonal antibody products used for PrEP of COVID-19 and their administration can be found on the CMS COVID-19 Vaccine Pricing website at <https://www.cms.gov/medicare/payment/fee-for->

service-providers/part-b-drugs/average-drug-sales-price/vaccine-pricing, under “COVID-19 Vaccines & Monoclonal Antibodies.”

III. BUSINESS REQUIREMENTS TABLE

"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.

Number	Requirement	Responsibility								Other
		A/B MAC			DM E MA C	Shared-System Maintainers				
		A	B	HH H		FIS S	MC S	VM S	CW F	
13861.1	The CMS shall notify the contractors when the 2025 Part B Vaccine Administration payment file is available for downloading in mid-November 2024, along with the file name, through an e-mail notification via the Parts A/B Functional Workgroup.									CMS
13861.1.1	Contractors shall retrieve, download, and apply the January 2025 annual vaccine administration payment file from the CMS mainframe for testing and production through the CDC on or after 11/13/2024. The filename is as follows: MU00.@BF12390.VAX2025.V1101	X	X							
13861.2	In the event that corrections are required, and a 2025 Part B Vaccine Administration replacement payment file is issued, contractors shall be prepared to retrieve and apply the replacement Part B Vaccine Administration payment file(s) from the CMS mainframe.	X	X							
13861.2.1	The CMS shall notify the contractors when the replacement file is available for retrieval, along with the file name, through an e-mail notification via the Part A/B Functional Workgroup.									CMS
13861.2.1.1	Contractors shall be ready to implement any replacement files no later than the January 6, 2025 implementation date of this CR, unless otherwise directed by	X	X							

Number	Requirement	Responsibility								
		A/B MAC			DM E MA C	Shared-System Maintainers				Othe r
		A	B	HH H		FIS S	MC S	VM S	CW F	
	CMS.									
13861.3	Contractors shall notify CMS of successful receipt of the file described in requirement 13861.1, and requirement 13861.2 when a replacement file is issued, via e-mail to price_file_receipt@cms.hhs.gov, stating the name of the file received (e.g., CLAB, Average Sales Price, etc.), and the entity for which it was received (i.e., include states, workload numbers, quarter, and if Part A, Part B, or both).	X	X							
13861.4	Contractors shall not apply beneficiary coinsurance or deductible for Part B Vaccine Administration HCPCS and Current Procedural Terminology codes listed on the Part B Vaccine Administration Fee Schedule.	X	X							

IV. PROVIDER EDUCATION

Medicare Learning Network® (MLN): CMS will develop and release national provider education content and market it through the MLN Connects® newsletter shortly after we issue the CR. MACs shall link to relevant information on your website and follow IOM Pub. No. 100-09 Chapter 6, Section 50.2.4.1 for distributing the newsletter to providers. When you follow this manual section, you don't need to separately track and report MLN content releases. You may supplement with your local educational content after we release the newsletter.

Impacted Contractors: A/B MAC Part A, A/B MAC Part B

V. SUPPORTING INFORMATION

Section A: Recommendations and supporting information associated with listed requirements: N/A

"Should" denotes a recommendation.

X-Ref Requirement Number	Recommendations or other supporting information:

Section B: All other recommendations and supporting information:N/A

VI. CONTACTS

Post-Implementation Contact(s): Contact your Contracting Officer's Representative (COR).

VII. FUNDING

Section A: For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

ATTACHMENTS: 0